A detailed history of Sg Americas Securities, LLC transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Sg Americas Securities, LLC holds 23,405 shares of TRVI stock, worth $64,363. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23,405
Holding current value
$64,363
% of portfolio
0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 03, 2024

BUY
$2.58 - $3.51 $60,384 - $82,151
23,405 New
23,405 $78,000
Q1 2024

May 06, 2024

SELL
$1.3 - $3.7 $108,759 - $309,545
-83,661 Reduced 85.15%
14,592 $50,000
Q4 2023

Jan 12, 2024

BUY
$1.06 - $2.05 $83,375 - $161,244
78,656 Added 401.37%
98,253 $132,000
Q3 2023

Oct 13, 2023

BUY
$2.11 - $2.47 $41,349 - $48,404
19,597 New
19,597 $43,000

Others Institutions Holding TRVI

About Trevi Therapeutics, Inc.


  • Ticker TRVI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,322,500
  • Market Cap $160M
  • Description
  • Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...
More about TRVI
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.